Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Thursday, August 21, 2008

BioVex granted U.K. study of genital herpes vaccine

By Mass High Tech Staff


BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has received British approval to begin a Phase 1 clinical study of its genital herpes vaccine  treatment, ImmunoVEX HSV2.

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the clinical trial application to examine safety and immunogenicity of the vaccine.

ImmunoVEX HSV2 operates by allowing the human immune system to build up a response to the presence of genital herpes, after the vaccine has effectively removed the gene that prevents herpes from making contact with the immune system.

Privately-held BioVex last reported closing a $35 million Series E round of funding in November 2007. The proceeds, the company said, would fund Phase 3 clinical trials of its lead melanoma drug as well as trials for its treatments for head and neck, and pancreatic cancers. BioVex also reported that the round would be used to advance studies of its ImmunoVEX HSV2 vaccine for genital herpes.





 

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Women to Watch: What makes them special

By James M. Connolly Intelligence, dedicated, leader, innovative, hard-working — they’re all words associated with the 11 women recognized with the Mass High Tech Women to Watch awards this morning. But back at the office we were talking how commonly another word has to be applied to the 2010 honorees and their 60 predecessors. It’s their humility. It’s so striking. We at Mass High T...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio